ATE440284T1 - Verwendung von adiponectin zur diagnose von krebs - Google Patents

Verwendung von adiponectin zur diagnose von krebs

Info

Publication number
ATE440284T1
ATE440284T1 AT04701189T AT04701189T ATE440284T1 AT E440284 T1 ATE440284 T1 AT E440284T1 AT 04701189 T AT04701189 T AT 04701189T AT 04701189 T AT04701189 T AT 04701189T AT E440284 T1 ATE440284 T1 AT E440284T1
Authority
AT
Austria
Prior art keywords
cancer
adiponectin
disclosed
epithelial
methods
Prior art date
Application number
AT04701189T
Other languages
English (en)
Inventor
Christos Mantzoros
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE440284T1 publication Critical patent/ATE440284T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04701189T 2003-01-09 2004-01-09 Verwendung von adiponectin zur diagnose von krebs ATE440284T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43908803P 2003-01-09 2003-01-09
PCT/US2004/000410 WO2004063711A2 (en) 2003-01-09 2004-01-09 Use of adiponectin to diagnose and treat malignancy

Publications (1)

Publication Number Publication Date
ATE440284T1 true ATE440284T1 (de) 2009-09-15

Family

ID=32713428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701189T ATE440284T1 (de) 2003-01-09 2004-01-09 Verwendung von adiponectin zur diagnose von krebs

Country Status (4)

Country Link
EP (1) EP1585987B1 (de)
AT (1) ATE440284T1 (de)
DE (1) DE602004022632D1 (de)
WO (1) WO2004063711A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005031345A2 (en) * 2003-09-27 2005-04-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
JP5386056B2 (ja) * 2003-11-04 2014-01-15 第一三共株式会社 抗腫瘍剤
US7749956B2 (en) 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7678886B2 (en) 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
US7592423B2 (en) 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
CA2707182C (en) 2007-11-30 2017-12-12 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
WO2010123720A1 (en) * 2009-04-23 2010-10-28 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
KR102402428B1 (ko) * 2021-06-18 2022-05-31 주식회사 레지온 난소암 진단용 다중 바이오 마커 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002546A1 (en) * 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 human secreted proteins
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
JPWO2002061076A1 (ja) * 2001-02-01 2004-06-03 持田製薬株式会社 アディポネクチン関連蛋白質

Also Published As

Publication number Publication date
EP1585987B1 (de) 2009-08-19
EP1585987A2 (de) 2005-10-19
WO2004063711A2 (en) 2004-07-29
WO2004063711A3 (en) 2004-09-16
DE602004022632D1 (de) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2006089212A3 (en) Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Hwang et al. Prognostic influence of BCL2 on molecular subtypes of breast cancer
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE440284T1 (de) Verwendung von adiponectin zur diagnose von krebs
Kachrilas et al. PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DK1631686T3 (da) Påvisning af dysplasi i høj grad i cervicale celler
DK2199801T3 (da) Biomarkører til tidlig påvisning af ovariecancer
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2020204373A3 (ko) 고형암 진단 장치와 고형암 진단 정보 제공 방법
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
Mhawech-Fauceglia et al. Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas
EP1539818A4 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
CY1109634T1 (el) Μεθοδος διαλογης ιχνηλατων pet για εγκαιρη παρακολουθηση της αντικαρκινικης θεραπειας
Hwang et al. A study on the relationships between osteoporosis knowledge, self-efficacy and health belief of women in an island
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
Maguire et al. Assay of E-cadherin by ELISA in human breast cancers
DE602004013554D1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
ATE409002T1 (de) Gerät für prostatekrebsdiagnose
DE602004025812D1 (de) N mammakarzinom
Vollmann‐Zwerenz et al. Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry—possibilities and limitations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties